BIOMAT Database Logo BIOMAT Database Logo

No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection. 1997

C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca

UI MeSH Term Description Entries
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D014766 Viremia The presence of viruses in the blood. Viremias
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016049 Didanosine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. 2',3'-Dideoxyinosine,Dideoxyinosine,ddI (Antiviral),NSC-612049,Videx,2',3' Dideoxyinosine,NSC 612049,NSC612049
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts

Related Publications

C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
June 1998, AIDS (London, England),
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
[Pancreatic disease in patients with HIV treated with didanosine (DDI)].
February 1996, Revista espanola de enfermedades digestivas,
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
July 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
June 1996, AIDS (London, England),
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.
February 2000, AIDS (London, England),
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Successful treatment of HIV-related thrombocytopenia with didanosine (ddI)
May 1994, Journal of acquired immune deficiency syndromes,
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.
October 2012, Journal of viral hepatitis,
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
January 2000, The Cochrane database of systematic reviews,
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
January 2000, The Cochrane database of systematic reviews,
C Simonelli, and M Comar, and S Zanussi, and P De Paoli, and U Tirelli, and M Giacca
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
July 2000, AIDS (London, England),
Copied contents to your clipboard!